The once-singular treatment option for metabolic dysfunction-associated steatohepatitis (MASH) is rapidly evolving into a dynamic and fiercely competitive therapeutic arena. Rezdiffra (resmetirom), the pioneering drug approved in March 2024, now finds itself the incumbent facing a two-pronged challenge from novel mechanisms of action, signaling a new era of rapid innovation and diverse treatment strategies for this pervasive liver disease.
For years, the medical community grappled with the immense challenge of effectively treating MASH, a condition affecting millions and a leading cause of liver transplantation in the US and Europe. The landscape was defined by a string of costly Phase III clinical trial failures, leaving a void in patient care. The arrival of Madrigal Pharmaceuticals’ Rezdiffra, an oral, liver-directed therapy that demonstrated improvement in liver fibrosis on biopsy, was hailed as a monumental breakthrough, offering a tangible glimmer of hope for patients and physicians alike. However, this period of solitary leadership has been remarkably short-lived.
The approval of semaglutide for MASH in August 2025 marked a significant turning point, transforming the market into a two-drug scenario and, more crucially, signaling the broader entry of the influential GLP-1 receptor agonist class into hepatology. This seismic shift was further underscored at the EASL Congress in Barcelona and the ADA meeting in New Orleans in late May 2026, where emerging data revealed a sophisticated, multi-faceted approach to tackling MASH. Rezdiffra is no longer the sole contender; it is now the benchmark against which new therapies, employing distinct mechanistic pathways, are being rigorously evaluated.
A Chronology of a Shifting Landscape
The narrative of MASH treatment evolution is a story of accelerating progress and the rapid diversification of therapeutic approaches.
- March 2024: Madrigal Pharmaceuticals’ resmetirom (Rezdiffra) receives FDA approval, marking the first-ever marketed drug for MASH. This oral, liver-directed therapy offers improvement in fibrosis on biopsy, a critical unmet need.
- August 2025: Semaglutide, a well-established GLP-1 receptor agonist, gains FDA approval for MASH. This dual approval transforms the market and signals the broader entry of the incretin class into liver disease treatment.
- May 2026 (EASL Congress, Barcelona): Altimmune presents encouraging, albeit mixed, 48-week data from its Phase IIb IMPACT trial of pemvidutide, a glucagon/GLP-1 dual receptor agonist. While meeting its primary endpoint of MASH resolution, it narrowly missed the secondary endpoint of fibrosis improvement on biopsy, despite positive non-invasive markers.
- June 2026 (ADA Meeting, New Orleans): Boehringer Ingelheim highlights positive Phase III SYNCHRONIZE program data for survodutide, its own glucagon/GLP-1 dual agonist, in patients with obesity and MASLD. Eli Lilly showcases comprehensive data for its triple GIP/GLP-1/glucagon agonist, retatrutide, as part of its broader Phase III readouts. Novo Nordisk presents new post-hoc analyses from the semaglutide ESSENCE trial.
- Late 2026 (Projected): Altimmune is expected to initiate its Phase III PERFORMA trial for pemvidutide, aiming to replicate the biopsy-proven fibrosis improvement seen in previous trials for Rezdiffra and semaglutide.
- Ongoing 2026: The field of FGF21 analogs continues to generate significant interest, with Akero Therapeutics’ efruxifermin demonstrating notable antifibrotic effects, including early signals of cirrhosis reversal.
Emerging Therapeutic Strategies and Supporting Data
The recent scientific congresses have illuminated two primary mechanistic directions challenging Rezdiffra’s initial dominance: dual-acting glucagon/GLP-1 agonists and the continued expansion of incretin-based therapies, alongside the persistent promise of FGF21 analogs.
The Rise of Dual Receptor Agonists: Pemvidutide and Survodutide
Altimmune’s pemvidutide, a 1:1 glucagon/GLP-1 dual receptor agonist, presented a compelling case at EASL 2026. The rationale behind its mechanism is twofold: leveraging the appetite suppression and weight loss effects of GLP-1 activation, while simultaneously employing glucagon receptor activation to directly target hepatic fat metabolism, reduce inflammation, and potentially mitigate fibrosis.
The 48-week data from the Phase IIb IMPACT trial showed encouraging results. At 24 weeks, the trial met its co-primary endpoint of MASH resolution without worsening of fibrosis, achieving this in up to approximately 59% of treated patients compared to placebo. Furthermore, it demonstrated significant reductions in liver fat (near 60%) and sustained weight loss of 5%-6% without evidence of a plateau. Crucially, pemvidutide exhibited best-in-class tolerability, with a low discontinuation rate (<1%) and no requirement for dose titration.
However, the trial narrowly missed its second co-primary endpoint, which required at least a one-stage improvement in fibrosis. This outcome was attributed, in part, to a high placebo response rate. Despite this, promising indications of antifibrotic activity were observed through non-invasive markers such as enhanced liver fibrosis (ELF) and liver stiffness, as well as digital pathology analysis. The critical hurdle for regulatory approval remains the demonstration of biopsy-confirmed fibrosis improvement, a standard that will be tested in the upcoming Phase III PERFORMA trial.
Boehringer Ingelheim’s survodutide, another glucagon/GLP-1 dual agonist, also garnered attention at the ADA meeting. Data from the Phase III SYNCHRONIZE program, focusing on patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), indicated positive outcomes. The trial met both co-primary endpoints, achieving normalization of liver fat (below 5%) in 61% of treated patients versus less than 6% on placebo. It also drove a significant relative liver fat reduction (at least 30%) in up to 84% of patients and resulted in substantial weight loss, averaging around 12%. While these results are promising for liver fat and weight management, it is important to note that this trial was not a histology and outcomes trial (like the LIVERAGE program) that will ultimately define survodutide’s MASH label. Nevertheless, the data lend further credence to the glucagon/GLP-1 mechanism’s potential in liver disease, particularly with its impressive weight loss profile.
The Enduring Power of Incretins and the Broader Metabolic Approach
The GLP-1 class, initially propelled by semaglutide’s MASH approval, continues to exert significant influence. Eli Lilly’s retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, was a highly anticipated presentation at ADA 2026. Its comprehensive data, including a dedicated MASLD program, further solidifies the potential of multi-agonist therapies in addressing metabolic derangements contributing to liver disease.
Novo Nordisk’s continued analysis of the semaglutide ESSENCE trial also reinforces the value of GLP-1s. The implication is that for many patients, the first MASH therapy they receive may well be a GLP-1 they are already taking for diabetes or weight management. This inherent advantage in patient access and existing prescription patterns presents a formidable distribution advantage that a liver-specific incumbent like Rezdiffra cannot easily replicate. This suggests a future where metabolic drugs could become a foundational element of MASH treatment, potentially integrated into existing patient care pathways.
FGF21 Analogs: A Focus on Fibrosis Reversal
While incretins and dual agonists target metabolic and inflammatory pathways, the FGF21 analog class is carving out a niche by focusing on antifibrotic mechanisms. This class has delivered some of the most compelling data regarding fibrosis regression, with Akero Therapeutics’ efruxifermin in the Phase IIb SYMMETRY study showing the first credible signals of cirrhosis reversal. Impressive antifibrotic results have also been reported for other FGF21 analogs, including efimosfermin and pegozafermin.
The significant potential of this class has been recognized through substantial industry activity. In 2025 alone, Novo Nordisk acquired Akero, Roche acquired 89bio, and GSK secured rights to efimosfermin from Boston Pharmaceuticals, underscoring the strategic importance of FGF21 analogs in the future MASH treatment paradigm.
Official Responses and Regulatory Considerations
The regulatory landscape for MASH treatment has been shaped by the approval of Rezdiffra and semaglutide. Both drugs were approved based on demonstrating improvement in liver fibrosis, a critical histological endpoint that regulators rely upon for drug approval.
- FDA’s Role: The US Food and Drug Administration (FDA) has set a precedent for MASH drug approvals, emphasizing biopsy-proven fibrosis improvement. This benchmark is a key determinant of success for emerging therapies. The FDA’s willingness to approve the first MASH drug, Rezdiffra, signaled a commitment to addressing this unmet medical need. The subsequent approval of semaglutide further demonstrated the agency’s receptiveness to therapies addressing the disease, particularly those with established safety profiles in related indications.
- Industry’s Adaptation: Pharmaceutical companies are acutely aware of the regulatory hurdles. The missed biopsy endpoint for pemvidutide, despite positive non-invasive markers, highlights the critical need to design Phase III trials that definitively meet regulatory requirements for fibrosis improvement. Companies are investing heavily in understanding and meeting these criteria, as evidenced by the planned Phase III PERFORMA trial for pemvidutide and the LIVERAGE program for survodutide.
Implications for the Future of MASH Treatment
The rapid evolution of the MASH therapeutic landscape has profound implications for patient care, pharmaceutical strategy, and the future of liver disease management.
The End Game: Combination Therapy and Stratification
The consensus is rapidly forming that MASH, a complex disease with interconnected metabolic, inflammatory, and fibrotic components, will ultimately be best treated with combination therapies. No single mechanism is likely to fully address the multifaceted nature of the disease.
- Rezdiffra’s Evolving Role: While Rezdiffra’s first-mover advantage, established safety profile, oral convenience, and liver-directed, weight-neutral profile provide it with a durable role, this role is likely to shift. It may transition from a primary monotherapy to a foundational component of combination regimens. Madrigal Pharmaceuticals is proactively adapting, expanding its pipeline to include 13 candidates and actively pursuing combination therapies. This includes exploring combinations of Rezdiffra with GLP-1 agonists, siRNA assets from Ribo, and Pfizer’s ervogastat, demonstrating a strategic pivot towards a multi-pronged approach.
- Novo Nordisk’s Strategic Advantage: Novo Nordisk is in a particularly strong position, holding both semaglutide, the first approved GLP-1 for MASH, and efruxifermin, a leading FGF21 antifibrotic. This dual ownership positions them to be a major player in developing and offering synergistic combination therapies.
- The Rise of Patient Stratification: As more therapeutic options emerge, the focus will inevitably shift towards patient stratification. Identifying which patients will benefit most from specific monotherapies or combination regimens will be crucial for optimizing treatment outcomes. This may involve advanced diagnostics to assess individual patient profiles, including the predominant drivers of their MASH.
Rezdiffra as a Benchmark, Not a Platform
The current trajectory suggests that Rezdiffra, while a significant breakthrough, may evolve into a benchmark against which other assets are measured, rather than serving as the sole platform upon which future therapies are built. The strong emphasis on incretins and FGF21 analogs indicates a preference for mechanisms that offer broader metabolic benefits or potent antifibrotic effects.
The ultimate success of Rezdiffra will hinge on its ability to integrate effectively into future combination strategies. Its value proposition will be amplified if its combination partners can meaningfully enhance its therapeutic status, allowing it to maintain a significant presence in an increasingly competitive and sophisticated MASH therapy landscape. The question has shifted from "can MASH be treated?" to "which diverse array of drug candidates, particularly in combination, will achieve the greatest success?" This dynamic environment promises exciting developments and improved outcomes for the millions affected by MASH.
About the Author
